AgeX Therapeutics announces a manufacturing, marketing and distribution agreement with Pluristyx, an advanced therapy tools and services company, to expand access to clinical-grade human pluripotent stem cells for therapeutic applications.
AgeX Therapeutics announced the online publication of data relating to regeneration, aging, and cancer in bioRxiv.
AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.
AgeX Therapeutics announced that ImStem has obtained a non-exclusive, royalty-bearing sublicense from AgeX for development of ImStem’s investigational product candidate IMS001 for development in COVID-19 and ARDS from other causes....
AgeX, a Juvenescence partner, and Sernova collaborate to utilize AgeX’s UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for the treatment of type I diabetes and hemophilia A.
AgeX Therapeutics, a Juvenescence partner, announced that ImStem Biotechnology has received notification from the FDA that it has cleared the investigational New Drug application to evaluate IMS001 for the treatment...
Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform. Goal of developing cellular therapies for Huntington’s disease and potentially Parkinson’s, Alzheimer’s and other neurological conditions. Builds on...
AgeX, a Juvenescence partner, announced a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.
At the end of its first year as a public company, Juvenescence partner AgeX issues a letter shareholders reflecting on progress made, as well as current initiatives and future plans.
AgeX Therapeutics, a biotechnology company, and Juvenescence, a biotech longevity company, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine.